Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer. 2012 Aug 1;118(15):3869-77. doi: 10.1002/cncr.26694. Epub 2011 Dec 16.
Cancer pain initiatives recommend using the personalized pain goal to tailor pain management. This study was conducted to examine the feasibility and stability of personalized pain goal, and how it compares to the clinical pain response criteria.
Records of 465 consecutive cancer patients seen in consultation at the Supportive Care Clinic were reviewed. Pain relief was assessed as clinical response (≥30% or ≥2 point pain reduction) and personalized pain goal response (pain ≤ personalized pain goal).
One hundred fifty-two (34%), 95 (21%), and 163 (37%) patients presented with mild (1-4), moderate (5-6), and severe (7-10) pain, respectively. Median age (59 years), males (52%), and advanced cancer status (84%) did not differ by pain category. Median personalized pain goal at initial clinic consult was 3 (interquartile range, 2-3), was similar across pain groups, and remained unchanged (P = .57) at follow-up (median, 14 days). Clinical response was higher among patients with severe pain (60%) as compared with moderate (40%) and mild pain (33%, P < .001). Personalized pain goal response was higher among patients with mild pain (63%) as compared with moderate (44%) and severe pain (27%, P < .001). By using personalized pain goal response as the gold standard for pain relief, the sensitivity of clinical response was highest (98%) among patients with severe pain, but it had low specificity (54%). In patients with mild pain, clinical response was most specific for pain relief (98%), but had low sensitivity (52%).
Personalized pain goal is a simple patient-reported outcome for pain goals. The majority of patients were capable of stating their desired level for pain relief. The median personalized pain goal was 3, and it was highly stable at follow-up assessment.
癌症疼痛倡议建议使用个性化疼痛目标来定制疼痛管理。本研究旨在检验个性化疼痛目标的可行性和稳定性,以及它与临床疼痛反应标准的比较。
回顾了在支持性护理诊所就诊的 465 例连续癌症患者的记录。疼痛缓解评估为临床反应(≥30%或≥2 点疼痛减轻)和个性化疼痛目标反应(疼痛≤个性化疼痛目标)。
分别有 152 例(34%)、95 例(21%)和 163 例(37%)患者表现为轻度(1-4)、中度(5-6)和重度(7-10)疼痛。中位数年龄(59 岁)、男性(52%)和晚期癌症状态(84%)在疼痛类别之间无差异。初始就诊时的中位数个性化疼痛目标为 3(四分位距,2-3),在疼痛组之间相似,在随访(中位数,14 天)时保持不变(P=.57)。严重疼痛患者的临床反应(60%)高于中度疼痛(40%)和轻度疼痛(33%,P <.001)。轻度疼痛患者的个性化疼痛目标反应(63%)高于中度疼痛(44%)和重度疼痛(27%,P <.001)。以个性化疼痛目标反应为疼痛缓解的金标准,严重疼痛患者的临床反应灵敏度最高(98%),但特异性(54%)较低。在轻度疼痛患者中,临床反应对疼痛缓解最特异(98%),但灵敏度(52%)较低。
个性化疼痛目标是一种简单的患者报告的疼痛目标结果。大多数患者能够说出他们希望的疼痛缓解水平。中位数个性化疼痛目标为 3,在随访评估时高度稳定。